{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:38:44Z","timestamp":1791221924863,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,6,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> In this randomized, phase III study, quality of life (QoL) was assessed in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) after high-dose radiotherapy alone or in combination with cetuximab. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients with stage III or IV nonmetastatic and measurable squamous cell carcinoma of the oropharynx, hypopharynx, or larynx were eligible. QoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and EORTC QLQ Head and Neck Cancer\u2013Specific Module at baseline, week 4, and at months 4, 8, and 12 postbaseline. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> In this study, one of the largest conducted in a population of patients with locoregionally advanced SCCHN, 424 patients received radiotherapy alone (213 patients) or radiotherapy plus cetuximab (211 patients). Radiotherapy\/cetuximab significantly improved locoregional control (P = .005) and overall survival (P = .03) compared with radiotherapy alone, without significantly increasing radiotherapy-associated adverse events. The current analysis focused on the impact of cetuximab on the QoL. Compliance with completion of QoL questionnaires was high in both arms. QoL worsened during treatment and improved after cessation of treatment, reaching baseline levels at 12 months. There were no significant differences in QoL scores between the treatment arms. This was particularly notable for global health status\/QoL, social functioning, social eating, and social contact. Pretreatment global health status\/QoL was identified as a significant prognostic variable in these patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> The addition of cetuximab to radiotherapy significantly improved locoregional control and increased overall survival without adversely affecting QoL. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2006.08.8005","type":"journal-article","created":{"date-parts":[[2007,5,30]],"date-time":"2007-05-30T22:29:10Z","timestamp":1180564150000},"page":"2191-2197","source":"Crossref","is-referenced-by-count":207,"title":["Quality of Life in Head and Neck Cancer Patients After Treatment With High-Dose Radiotherapy Alone or in Combination With Cetuximab"],"prefix":"10.1200","volume":"25","author":[{"given":"Desmond","family":"Curran","sequence":"first","affiliation":[{"name":"From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Giralt","sequence":"additional","affiliation":[{"name":"From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Harari","sequence":"additional","affiliation":[{"name":"From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Kian","family":"Ang","sequence":"additional","affiliation":[{"name":"From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrill S.","family":"Kies","sequence":"additional","affiliation":[{"name":"From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Jassem","sequence":"additional","affiliation":[{"name":"From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Baselga","sequence":"additional","affiliation":[{"name":"From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric K.","family":"Rowinsky","sequence":"additional","affiliation":[{"name":"From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Amellal","sequence":"additional","affiliation":[{"name":"From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Comte","sequence":"additional","affiliation":[{"name":"From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Bonner","sequence":"additional","affiliation":[{"name":"From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200006000-00003"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Morris J: Widening perspectives: Quality of life as a measure of outcome in the treatment of patients with cancers of the head and neck. Eu J Cancer B Oral Oncol 30B:29,1994-31,","DOI":"10.1016\/0964-1955(94)90047-7"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1002\/hed.10206"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199301213280306"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20069"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/S0964-1955(96)00069-3"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10257"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806183382503"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Harari PM: Promising new advances in head and neck radiotherapy. Ann Oncol 16:vi13,2005-vi19,  (suppl 6)","DOI":"10.1093\/annonc\/mdi453"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.24.2081"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.1020"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1007\/BF03038560"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.124.9.964"},{"key":"R14","unstructured":"Goldstein NI, Prewett M, Zuklys K, et al: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311,1995-1318,"},{"key":"R15","unstructured":"Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350,2002-7356,"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.10.014"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3234"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:568,2006-578,","DOI":"10.1056\/NEJMoa053422"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1188\/05.CJON.332-338"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Hollywood E: Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225. Semin Oncol Nurs 18:30,2002-35,  (suppl 2)","DOI":"10.1053\/sonu.2002.33070"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Riddle J, Lee P, Purdom M: The epidermal growth factor receptor as a novel target for cancer therapy: Case studies and clinical implications. Semin Oncol Nurs 18:11,2002-19,  (suppl 4)","DOI":"10.1053\/sonu.2002.37407"},{"key":"R22","unstructured":"Fayers PM, Aaronson NK, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual  (ed 9). Brussels, Belgium, EORTC, 1999"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00186-6"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<711::AID-SIM816>3.0.CO;2-H"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00056-3"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<697::AID-SIM815>3.0.CO;2-Y"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<653::AID-SIM812>3.0.CO;2-M"},{"key":"R28","unstructured":"Diggle PJ, Liang KY, Zeger SL: Analysis of Longitudinal Data . Oxford, United Kingdom, Clarendon Press, 1994"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Verbeke G, Molenberghs G: Linear Mixed Models in Practice . New York, NY, Springer-Verlag, 1997","DOI":"10.1007\/978-1-4612-2294-1"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1191\/0962280202sm270ra"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2003.10.002"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000158837.47450.81"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0347(199809)20:6<540::AID-HED9>3.0.CO;2-J"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00385-3"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.08.8005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:03:52Z","timestamp":1653509032000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.08.8005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,1]]},"references-count":35,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2007,6,1]]}},"alternative-id":["10.1200\/JCO.2006.08.8005"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.08.8005","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,1]]}}}